CA3234214A1 - Methods for determining mutations for increasing modified replicable rna function and related compositions and their use - Google Patents
Methods for determining mutations for increasing modified replicable rna function and related compositions and their use Download PDFInfo
- Publication number
- CA3234214A1 CA3234214A1 CA3234214A CA3234214A CA3234214A1 CA 3234214 A1 CA3234214 A1 CA 3234214A1 CA 3234214 A CA3234214 A CA 3234214A CA 3234214 A CA3234214 A CA 3234214A CA 3234214 A1 CA3234214 A1 CA 3234214A1
- Authority
- CA
- Canada
- Prior art keywords
- rrna
- rna
- modified
- sequence
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021078828 | 2021-10-18 | ||
| EPPCT/EP2021/078828 | 2021-10-18 | ||
| PCT/EP2022/078869 WO2023066874A1 (en) | 2021-10-18 | 2022-10-17 | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234214A1 true CA3234214A1 (en) | 2023-04-27 |
Family
ID=78483247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234214A Pending CA3234214A1 (en) | 2021-10-18 | 2022-10-17 | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250250626A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4419708A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024539089A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118451194A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022372325A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234214A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023066874A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025129137A1 (en) * | 2023-12-14 | 2025-06-19 | Amplitude Therapeutics, Inc. | Two-component platform for trans amplifying rna (tarna) vaccination |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4522754A1 (en) * | 2022-05-12 | 2025-03-19 | Sunvax MRNA Therapeutics Inc. | Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator |
| WO2025040709A1 (en) | 2023-08-24 | 2025-02-27 | BioNTech SE | Systems and compositions comprising highly active trans-amplifying replicases |
| CN122514603A (zh) * | 2023-11-02 | 2026-08-04 | 安普利特治疗公司 | 包含经化学修饰的核碱基的反式扩增rna |
| CN120379688A (zh) * | 2024-01-24 | 2025-07-25 | 南京金斯瑞生物科技有限公司 | 一种自复制rna及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119827A1 (en) | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| US8153773B2 (en) | 2007-06-19 | 2012-04-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
| CN101848936B (zh) | 2007-08-20 | 2017-05-03 | 葛兰素集团有限公司 | 生产方法 |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| RS63890B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Mali lipozomi za isporuku rnk koja kodira imunogen |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするrnaの送達のためのpeg化リポソーム |
| RU2014104090A (ru) | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
| US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| PT2750707T (pt) | 2011-08-31 | 2019-01-23 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para distribuição de arn que codifica imunogénio |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| AU2018333530B2 (en) * | 2017-09-13 | 2024-05-30 | Biontech Cell & Gene Therapies Gmbh | RNA replicon for expressing a T cell receptor or an artificial T cell receptor |
| WO2020146690A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Methods for in vitro evolution of rna replicons |
| JP2023521662A (ja) * | 2020-04-03 | 2023-05-25 | グリットストーン バイオ インコーポレイテッド | 感染症抗原及びワクチン |
-
2022
- 2022-10-17 EP EP22802971.6A patent/EP4419708A1/en active Pending
- 2022-10-17 CN CN202280069737.1A patent/CN118451194A/zh active Pending
- 2022-10-17 AU AU2022372325A patent/AU2022372325A1/en active Pending
- 2022-10-17 CA CA3234214A patent/CA3234214A1/en active Pending
- 2022-10-17 US US18/702,287 patent/US20250250626A1/en active Pending
- 2022-10-17 WO PCT/EP2022/078869 patent/WO2023066874A1/en not_active Ceased
- 2022-10-17 JP JP2024523403A patent/JP2024539089A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025129137A1 (en) * | 2023-12-14 | 2025-06-19 | Amplitude Therapeutics, Inc. | Two-component platform for trans amplifying rna (tarna) vaccination |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023066874A1 (en) | 2023-04-27 |
| EP4419708A1 (en) | 2024-08-28 |
| AU2022372325A1 (en) | 2024-05-02 |
| JP2024539089A (ja) | 2024-10-28 |
| CN118451194A (zh) | 2024-08-06 |
| US20250250626A1 (en) | 2025-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2748892C2 (ru) | Рнк-репликон для универсальной и эффективной генной экспрессии | |
| RU2752580C2 (ru) | Транс-реплицирующая рнк | |
| US20250250626A1 (en) | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use | |
| JP7769644B2 (ja) | 多用途かつ効率的な遺伝子発現のためのrnaレプリコン | |
| US20250281602A1 (en) | Replicon Compositions and Methods of Using Same for the Treatment of Diseases | |
| US20250236883A1 (en) | Modified replicable rna and related compositions and their use | |
| WO2025040709A1 (en) | Systems and compositions comprising highly active trans-amplifying replicases | |
| HK40094277A (en) | Rna replicon for versatile and efficient gene expression | |
| HK40059264A (en) | Trans-replicating rna | |
| HK40023272A (en) | Rna replicon for versatile and efficient gene expression | |
| HK40023272B (en) | Rna replicon for versatile and efficient gene expression | |
| HK1259449B (en) | Rna replicon for versatile and efficient gene expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240918 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250925 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250925 |